Rhonda Farnum Sells 31,067 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Theravance Biopharma Trading Up 1.3%

Shares of NASDAQ:TBPH opened at $14.01 on Friday. The company has a 50 day moving average of $18.10 and a 200 day moving average of $16.84. The stock has a market cap of $709.89 million, a P/E ratio of 24.58 and a beta of 0.17. Theravance Biopharma, Inc. has a 12 month low of $7.90 and a 12 month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.71. The business had revenue of $45.89 million for the quarter, compared to analysts’ expectations of $43.09 million. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. On average, equities analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Theravance Biopharma

A number of large investors have recently added to or reduced their stakes in TBPH. Quarry LP purchased a new position in shares of Theravance Biopharma in the 3rd quarter worth about $26,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 515 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 1,411 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after buying an additional 4,662 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TBPH shares. BTIG Research dropped their price objective on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Wall Street Zen cut Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. Finally, HC Wainwright raised their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.60.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.